| Status: Recommended | |||
Lurasidone (Latuda®) is recommended as an option for use within NHS Wales for the treatment of schizophrenia in adults and adolescents aged 13 years and over. |
|||
|
|||
Medicine details |
|||
| Medicine name | lurasidone (Latuda®) | ||
| Formulation | 18.5 mg, 37 mg and 74 mg film-coated tablet | ||
| Reference number | 4394 | ||
| Indication | Treatment of schizophrenia in adults and adolescents aged 13 years and over |
||
| Company | Sunovion Pharmaceuticals Europe Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Licence extension for paediatric use | ||
| Status | Recommended | ||
| Advice number | 0421 | ||
| AWMSG meeting date | 10/03/2021 | ||
| Date of issue | 17/03/2021 | ||
| Further information This advice incorporates and replaces the AWMSG recommendation for lurasidone (Latuda®) for the treatment of schizophrenia in adults aged 18 years and over (advice number 0115, originally published February 2015). |
|||